DC Chemicals · Product datasheet

PD168393 — Datasheet

CAT. NO. DC9258

Product page and current package options

ParameterValue
Chemical NamePD168393
CAS No.194423-15-9
SynonymsPD 168393;N-[4-(3-bromoanilino)quinazolin-6-yl]prop-2-enamide;N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-propenamide;4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline;AC1L1IRY;AC1Q26CC;N-(4-(3-bromophenylamino)quinazoline-6-yl)acrylamide;N-[4-[(3-bromophenyl)-amino]-quinazolin-6-yl]-acrylamide;N-[4-[(3-Bromophenyl)amino]quinazolin-6-yl]-acrylamide;n-{4-[(3-bromophenyl)amino]quinazolin-6-yl}prop-2-enamide;nchembio866-comp2;PD-168393;SureCN2680536;N-(4-((3-Bromophenyl)amino)quinazolin-6-yl)acrylamide;2-Propenamide, N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-;PD168393;3R996Y9T0I;C17H13BrN4O;N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide;2-Propenamide, N-(4-((3-bromophenyl)amino)-6-quinazolinyl)-;N;4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline; N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-propenamide;BDBM4567;s7039;SCHEMBL2680536;NCGC00386260-01;CHEMBL285063;PD 168393 [WHO-DD];AC-32813;N-(4-(3-Bromophenylamino)quinazolin-6-yl)acrylamide;AKOS027337569;PD168393?;N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}prop-2-enamide;4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline;MFCD02179207;3968-03-4;NCGC00386260-02;CHEBI:131504;DTXSID80274444;HMS3652F18;SW218184-2;BCP07986;J-012594;DA-43376;PD168393, >=98% (HPLC);CCG-268278;EX-A808;NS00068483;HSCI1_000120;HTUBKQUPEREOGA-UHFFFAOYSA-N;CS-5723;4-anilinoquinazoline deriv. 2;BMC163482 Compound 1;SB19366;Q26998221;AS-67687;194423-15-9;F13662;HY-13896;N-[4-[(3-bromophenyl)amino]quinazolin-6-yl]acrylamide;DB07662;UNII-3R996Y9T0I;BRD-K17702546-001-03-2
FormulaC17H13BrN4O
M.Wt369.215322256088
SMILESBrC1=CC=CC(=C1)NC1=C2C=C(C=CC2=NC=N1)NC(C=C)=O
Purity>98%
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

PD168393 is an potent, cell-permeable, irreversible EGFR inhibitor with IC50 of 0.70 nM, irreversibly alkylate Cys-773, inactive against insulin, PDGFR, FGFR and PKC. target: EGFRIC 50: 0.7 nM [1](1) PD 168393 inhibite EGFr autophosphorylation in A431 human epidermoid carcinoma cells with >9-fold greater potency than PD 174265.[1](2) PD 168393 decrease the production of TNF-α and phosphrylation of ERK1/2 and p38 induced by LPS in cardiomyocytes.[2](3) PD168393 completely inhibits AKT and ERK phosphorylation at concentrations as low as 0.03 umol/L.[3](4) PD168393 could induce apoptosis and inhibit cell growth in ErbB2 positive lung and breast cancer cell lines.[3](5) PD168393 disrupted MEK1/p44/42 ERK signaling in HaCaT cells as determined by inhibition of phospho-p44/42 ERK. [4]

In Vitro

No in vitro data are provided in the current product source. Contact us for further information.

In Vivo

No in vivo data are provided in the current product source. Contact us for further information.

References & source

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.

Cart

Request quotation